XML 138 R82.htm IDEA: XBRL DOCUMENT v3.20.1
Total revenues and other income - Recognition of payments (Details)
€ in Thousands, $ in Thousands
 12 Months Ended
Aug. 23, 2019
USD ($)
Aug. 23, 2019
EUR (€)
Jul. 14, 2019
USD ($)
Jul. 14, 2019
EUR (€)
Dec. 31, 2019
EUR (€)
Dec. 31, 2018
USD ($)
Dec. 31, 2018
EUR (€)
Dec. 31, 2017
USD ($)
Dec. 31, 2017
EUR (€)
Dec. 31, 2016
EUR (€)
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront received     $ 3,950,000 € 3,569,800            
Upfront Payment Received $ 3,950,000 € 3,569,800                
Deferred income         € 3,000,646   € 149,801   € 219,892 € 285,612
Revenue recognized         844,985   288,836   127,087  
Gilead                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront received         € 3,569,815          
Gilead | Collaboration agreement for filgotinib, Milestone payments, Current Period [member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront received | $           $ 15,000        
Upfront Payment Received             12,418      
Gilead | Collaboration agreement for filgotinib, Upfront payment, Prior Period [member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront received | $               $ 300,000    
Upfront Payment Received                 275,558  
Gilead | Collaboration agreement for filgotinib, Subscription agreement, Prior Period [member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront Payment Received                 39,003  
Deferred income                 39,000  
Gilead | Collaboration agreement for filgotinib, Milestone payments, Prior Period [member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront received | $               70,000    
Upfront Payment Received                 64,435  
Servier | Collaboration agreement for osteoarthritis, Milestone payment, Current Period [member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront Payment Received             9,000      
Servier | Collaboration agreement for osteoarthritis, License fee, Prior Period [member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront Payment Received                 6,000  
AbbVie | Collaboration agreement for CF, Upfront payment, Current Period [member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront received | $           45,000        
Upfront Payment Received             38,874      
AbbVie | Collaboration agreement for CF, Milestone payments, Current Period [member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront received | $           $ 10,000        
Upfront Payment Received             8,548      
AbbVie | Collaboration agreement for CF, Upfront payments, Prior Period [member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront received | $               45,000    
Upfront Payment Received                 34,001  
AbbVie | Collaboration agreement for CF, Milestone payments, Prior Period [member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront received | $               $ 77,500    
Upfront Payment Received                 68,310  
Novartis | Collaboration Agreement for MOR106, Upfront Payment, Current Period [Member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront Payment Received             47,500      
IAS18                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue recognized             232,800   127,087  
IAS18 | Upfront and Milestone Payments and License Fees [Member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue recognized             213,845      
IAS18 | Upfront and Milestone Payments and License Fees Current Period [Member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue recognized             115,503      
IAS18 | Upfront Payments and License Fees, Current Period [Member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue recognized             85,537      
IAS18 | Milestone Payments for Current Period [Member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue recognized             29,966      
IAS18 | Upfront and Milestone Payments and License Fees, Prior Period [Member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred income                 219,343  
Revenue recognized             98,342   114,921  
IAS18 | Upfront Payments and License Fees, Prior Period [Member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred income                 219,343  
Revenue recognized             98,342   71,971  
IAS18 | Milestone Payments for Prior Period [Member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue recognized                 42,950  
IAS18 | Gilead | Collaboration agreement for filgotinib, Milestone payments, Current Period [member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue recognized             12,418      
IAS18 | Gilead | Collaboration agreement for filgotinib, Upfront payment, Prior Period [member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred income                 187,449  
Revenue recognized             84,806   62,488  
IAS18 | Gilead | Collaboration agreement for filgotinib, Subscription agreement, Prior Period [member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred income                 26,532  
Revenue recognized             12,004   8,845  
IAS18 | Gilead | Collaboration agreement for filgotinib, Milestone payments, Prior Period [member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue recognized                 9,354  
IAS18 | Servier | Collaboration agreement for osteoarthritis, Milestone payment, Current Period [member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue recognized             9,000      
IAS18 | Servier | Collaboration agreement for osteoarthritis, License fee, Prior Period [member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred income                 5,362  
Revenue recognized             1,532   638  
IAS18 | AbbVie | Collaboration agreement for CF, Upfront payment, Current Period [member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue recognized             38,037      
IAS18 | AbbVie | Collaboration agreement for CF, Milestone payments, Current Period [member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue recognized             8,548      
IAS18 | AbbVie | Collaboration agreement for CF, Milestone payments, Prior Period [member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue recognized                 33,596  
IAS18 | Novartis | Collaboration Agreement for MOR106, Upfront Payment, Current Period [Member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue recognized             47,500      
IFRS 15                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue recognized             288,836      
IFRS 15 | Upfront and Milestone Payments and License Fees [Member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred income             149,021      
Revenue recognized             269,881      
IFRS 15 | Upfront and Milestone Payments and License Fees Current Period [Member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred income             5,646      
Revenue recognized             110,694      
IFRS 15 | Upfront Payments and License Fees, Current Period [Member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred income             837      
Revenue recognized             85,537      
IFRS 15 | Milestone Payments for Current Period [Member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred income             4,809      
Revenue recognized             25,157      
IFRS 15 | Upfront and Milestone Payments and License Fees, Prior Period [Member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred income             143,375   302,563  
Deferred income reclassified from equity                 83,220  
Revenue recognized             159,187      
IFRS 15 | Upfront Payments and License Fees, Prior Period [Member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred income             117,903   228,853  
Deferred income reclassified from equity                 9,510  
Revenue recognized             110,950      
IFRS 15 | Milestone Payments for Prior Period [Member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred income             25,472   73,710  
Deferred income reclassified from equity                 73,710  
Revenue recognized             48,237      
IFRS 15 | Gilead | Collaboration agreement for filgotinib, Milestone payments, Current Period [member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred income             4,625      
Revenue recognized             7,793      
IFRS 15 | Gilead | Collaboration agreement for filgotinib, Upfront payment, Prior Period [member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred income             102,643   187,449  
Revenue recognized             84,806      
IFRS 15 | Gilead | Collaboration agreement for filgotinib, Subscription agreement, Prior Period [member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred income             14,528   26,532  
Revenue recognized             12,004      
IFRS 15 | Gilead | Collaboration agreement for filgotinib, Milestone payments, Prior Period [member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred income             24,001   43,832  
Deferred income reclassified from equity                 43,832  
Revenue recognized             19,831      
IFRS 15 | Servier | Collaboration agreement for osteoarthritis, Milestone payment, Current Period [member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue recognized             9,000      
IFRS 15 | Servier | Collaboration agreement for osteoarthritis, License fee, Prior Period [member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred income reclassified from equity                 (5,362)  
IFRS 15 | AbbVie | Collaboration agreement for CF, Upfront payment, Current Period [member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred income             837      
Revenue recognized             38,037      
IFRS 15 | AbbVie | Collaboration agreement for CF, Milestone payments, Current Period [member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred income             184      
Revenue recognized             8,364      
IFRS 15 | AbbVie | Collaboration agreement for CF, Upfront payments, Prior Period [member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred income             732   14,872  
Deferred income reclassified from equity                 14,872  
Revenue recognized             14,140      
IFRS 15 | AbbVie | Collaboration agreement for CF, Milestone payments, Prior Period [member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred income             1,471   29,878  
Deferred income reclassified from equity                 € 29,878  
Revenue recognized             28,406      
IFRS 15 | Novartis | Collaboration Agreement for MOR106, Upfront Payment, Current Period [Member]                    
IFRS Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue recognized             € 47,500